SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 6.86% Stake in PTC Therapeutics
Beneficial Ownership Disclosure
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 5,434,843 shares, representing 6.86% of PTC Therapeutics, Inc.'s common stock.
Summary
- Armistice Capital, LLC and Steven Boyd (the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in PTC Therapeutics, Inc.
- As of March 31, 2025, the Reporting Persons collectively beneficially own 5,434,843 shares of PTC Therapeutics, Inc. common stock.
- This ownership represents 6.86% of the Issuer's common stock.
- Armistice Capital, LLC, as the investment manager, and Steven Boyd, as its managing member, exercise shared voting and dispositive power over these shares.
- The percentage is calculated based on 79,257,019 shares outstanding as of May 4, 2025, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 6, 2025.
- The direct holder of the shares is Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and an investment advisory client of Armistice Capital.
Sentiment
Score: 5
Explanation: Neutral. This is a factual disclosure of beneficial ownership, not an operational or financial performance report. The maintenance of a significant stake by an institutional investor could be seen as mildly positive, but the document itself is neutral in tone and content regarding company performance.
Positives
- Armistice Capital, a significant institutional investor, maintains a substantial stake of 6.86% in PTC Therapeutics, indicating continued interest and confidence in the company.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
NA
Comparison to Industry Standards
- NA
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence investor sentiment and perception of stability.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement |
| 05/04/2025 | Date as of which 79,257,019 shares outstanding were reported by the Issuer |
| 05/06/2025 | Date Issuer's Form 10-Q was filed with the SEC, reporting shares outstanding |
| 05/15/2025 | Date of signing of the Schedule 13G/A filing by Armistice Capital, LLC and Steven Boyd |
Keywords
PTC Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.